Tag: source

BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

New York, NY, July 02, 2025 (GLOBE NEWSWIRE) -- LocalRank.so, the all-in-one local SEO platform built for agencies, announced today it has officially surpassed 2 million citations placed across its growing customer base — a major milestone that reinforces its position as the go-to platform for scalable, accurate, and agency-friendly local citation services.

OKOTOKS, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- (TSX: MTL) Mullen Group Ltd. ("Mullen Group" and/or the "Corporation") intends to release its 2025 Second Quarter earnings results on Thursday, July 24, 2025, at 6:00 a.m. ET, and has scheduled a conference call and webcast as follows:

SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Conference Call Scheduled for 8:00 a.m. ET on July 31, 2025

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.